7. Literaturverzeichnis

1 Schwab,U. *et al.* Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. *Nature* **299**, 65-67 (1982).

2 Stein,H. *et al.* The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. *Blood* **66**, 848-858 (1985).

3 Pallesen,G. & Hamilton-Dutoit,S.J. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. *Am. J. Pathol.* **133**, 446-450 (1988).

4 Garcia-Prats,M.D., Ballestin,C., Sotelo,T., Lopez-Encuentra,A. & Mayordomo,J.I. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. *Histopathology* **32**, 462-472 (1998).

5 Ito,K. *et al.* High expression of the CD30 molecule in human decidual cells. *Am. J. Pathol.* **145**, 276-280 (1994).

6 Dürkop,H. *et al.* Expression of the CD30 antigen in non-lymphoid tissues and cells. *J Pathol* **190**, 613-618 (2000).

7 Ellis,T.M., Simms,P.E., Slivnick,D.J., Jack,H.M. & Fisher,R.I. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. *J. Immunol.* **151**, 2380-2389 (1993).

8 Agrawal,B., Reddish,M. & Longenecker,B.M. CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors. *J. Immunol.* **157**, 3229-3234 (1996).

9 Andreesen,R., Osterholz,J., Lohr,G.W. & Bross,K.J. A Hodgkin cell-specific antigen is expressed on a subset of auto- and alloactivated T (helper) lymphoblasts. *Blood* **63**, 1299-1302 (1984).

10 Pizzolo,G. *et al.* High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. *AIDS* **8**, 741-745 (1994).

11 Fattovich,G. *et al.* Serum levels of soluble CD30 in chronic hepatitis B virus infection. *Clin. Exp. Immunol.* **103**, 105-110 (1996).

12 Wang,G. *et al.* High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis. *Am. J. Med.* **102**, 517-523 (1997).

13 Caligaris-Cappio,F. *et al.* Circulating levels of soluble CD30, a marker of cells producing Th2- type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. *Clin. Exp. Rheumatol.* **13**, 339-343 (1995).

14 Gerli,R. *et al.* High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. *Clin. Exp. Immunol.* **102**, 547-550 (1995).

15 Josimovic-Alasevic,O. *et al.* Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. *Eur. J. Immunol.* **19**, 157-162 (1989).

16 Pfreundschuh,M. *et al.* Detection of a soluble form of the CD30 antigen in sera of patients with lymphoma, adult T-cell leukemia and infectious mononucleosis. *Int. J. Cancer* **45**, 869-874 (1990).

17 Nadali,G. *et al.* Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma. *J Clin Oncol* **13**, 1355-1360 (1995).

18 Hansen,H.P. *et al.* A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. *Int. J. Cancer* **63**, 750-756 (1995).

19 Shulman,L.N. *et al.* Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome. *J. Clin. Oncol.* **11**, 937-942 (1993).

20 Greer,J.P. *et al.* Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma [see comments]. *J. Clin. Oncol.* **9**, 539-547 (1991).

21 Reiter,A. *et al.* Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. *J Clin Oncol* **12**, 899-908 (1994).

22 Zinzani,P.L. *et al.* Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients [see comments]. *J. Clin. Oncol.* **14**, 955-962 (1996).

23 Nakamura,S. *et al.* Clinicopathologic study of large cell anaplastic lymphoma (Ki-1-positive large cell lymphoma) among the Japanese. *Cancer* **68**, 118-129 (1991).

24 Dürkop,H. *et al.* Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. *Cell* **68**, 421-427 (1992).

25 Fleisher,A.S. *et al.* Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and

diminished expression of the DNA mismatch repair gene, hMLH1. *Cancer Res* **60**, 4864-4868 (2000).

26 Zhu,Y.M., Das-Gupta,E.P. & Russell,N.H. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. *Blood* **94**, 733-740 (1999).

27 Simpkins,S.B. *et al.* MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. *Hum Mol Genet* **8**, 661-666 (1999).

28 Biden,K.G. *et al.* Expression of Bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability. *Oncogene* **18**, 1245-1249 (1999).

29 Meloni,R., Albanese,V., Ravassard,P., Treilhou,F. & Mallet,J. A tetranucleotide polymorphic microsatellite, located in the first intron of the tyrosine hydroxylase gene, acts as a transcription regulatory element in vitro. *Hum Mol Genet* **7**, 423-428 (1998).

30 Vogelstein,B. & Gillespie,D. Preparative and analytical purification of DNA from agarose. *Proc Natl Acad Sci U S A* **76**, 615-619 (1979).

31 Southern,E.M. An improved method for transferring nucleotides from electrophoresis strips to thin layers of ion-exchange cellulose. *Anal Biochem* **62**, 317-318 (1974).

32 Birnboim,H.C. & Doly,J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. *Nucleic Acids Res* **7**, 1513-1523 (1979).

33 Senapathy,P., Shapiro,M.B. & Harris,N.L. Splice junctions, branch point sites, and exons: sequence statistics, identification, and applications to genome project. *Methods Enzymol* **183**, 252-278 (1990).

34 Shapiro,M.B. & Senapathy,P. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. *Nucleic Acids Res* **15**, 7155-7174 (1987).

35 Burke,T.W. & Kadonaga,J.T. Drosophila TFIID binds to a conserved downstream basal promoter element that is present in many TATA-box-deficient promoters. *Genes Dev* **10**, 711-724 (1996).

36 Burke,T.W. & Kadonaga,J.T. The downstream core promoter element, DPE, is conserved from Drosophila to humans and is recognized by TAFII60 of Drosophila. *Genes Dev* **11**, 3020-3031 (1997).

37 Lo,K. & Smale,S.T. Generality of a functional initiator consensus sequence. *Gene* **182**, 13-22 (1996).

38 Fuchs,P., Strehl,S., Dworzak,M., Himmler,A. & Ambros,P.F. Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13 [corrected]. *Genomics* **13**, 219-224 (1992).

39 Beltinger,C.P. *et al.* Physical mapping and genomic structure of the human TNFR2 gene. *Genomics* **35**, 94-100 (1996).

40 Loenen,W.A. *et al.* Genomic organization and chromosomal localization of the human CD27 gene. *J Immunol* **149**, 3937-3943 (1992).

41 Cheng,J., Liu,C., Koopman,W.J. & Mountz,J.D. Characterization of human Fas gene. Exon/intron organization and promoter region. *J Immunol* **154**, 1239-1245 (1995).

42 Dürkop,H. *et al.* Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. *Cell* **68**, 421-427 (1992).

43 Duckett,C.S., Gedrich,R.W., Gilfillan,M.C. & Thompson,C.B. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. *Mol. Cell Biol.* **17**, 1535-1542 (1997).

44 Boucher,L.M., Marengere,L.E., Lu,Y., Thukral,S. & Mak,T.W. Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. *Biochem. Biophys. Res. Commun.* **233**, 592-600 (1997).

45 Gedrich,R.W., Gilfillan,M.C., Duckett,C.S., Van Dongen,J.L. & Thompson,C.B. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. *J. Biol. Chem.* **271**, 12852-12858 (1996).

46 Horie,R. *et al.* A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages. *Blood* **88**, 2422-2432 (1996).

47 Smith,C.A., Farrah,T. & Goodwin,R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. *Cell* **76**, 959-962 (1994).

48 Naismith,J.H. & Sprang,S.R. Modularity in the TNF-receptor family. *Trends Biochem Sci* **23**, 74-79 (1998).

49 Kemper,O. & Wallach,D. Cloning and partial characterization of the promoter for the human p55 tumor necrosis factor (TNF) receptor. *Gene* **134**, 209-216 (1993).

50 Rothe,J., Bluethmann,H., Gentz,R., Lesslauer,W. & Steinmetz,M. Genomic organization and promoter function of the murine tumor necrosis factor receptor beta gene. *Mol Immunol* **30**, 165-175 (1993).

51 Behrmann,I., Walczak,H. & Krammer,P.H. Structure of the human APO-1 gene. *Eur J Immunol* **24**, 3057-3062 (1994).

52 Rudert,F. *et al.* Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/APO-1) gene. *DNA Cell Biol* **14**, 931-937 (1995).

53 Smale,S.T. & Baltimore,D. The "initiator" as a transcription control element. *Cell* **57**, 103-113 (1989).

54 Frank,M.B., Watson,J., Mochizuki,D. & Gillis,S. Biochemical and biologic characterization of lymphocyte regulatory molecules. VIII. Purification of interleukin 2 from a human T cell leukemia. *J. Immunol.* **127**, 2361-2365 (1981).

55 Dürkop,H. *et al.* The restricted expression pattern of the Hodgkin's lymphoma-associated cytokine receptor CD30 is regulated by a minimal promoter [In Process Citation]. *J Pathol* **192**, 182-193 (2000).

56 Croager,E.J., Muir,T.M. & Abraham,L.J. Analysis of the human and mouse promoter region of the non-Hodgkin's lymphoma-associated CD30 gene. *J. Interferon Cytokine Res.* **18**, 915-920 (1998).

57 Hodges,K.B., Vnencak-Jones,C.L., Larson,R.S. & Kinney,M.C. Rarity of genomic instability in pathogenesis of systemic anaplastic large cell lymphoma (ALCL) in immunocompetent patients. *Hum Pathol* **30**, 173-177 (1999).

58 Mark,Z. *et al.* Instability of dinucleotide repeats in Hodgkin's disease. *Am J Hematol* **57**, 148-152 (1998).

59 Catasti,P., Chen,X., Mariappan,S.V., Bradbury,E.M. & Gupta,G. DNA repeats in the human genome. *Genetica* **106**, 15-36 (1999).

60 Dynan,W.S. & Tjian,R. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. *Cell* **35**, 79-87 (1983).

61 Tamura,T. & Mikoshiba,K. Role of a GC-rich motif in transcription regulation of the adenovirus type 2 IVa2 promoter which lacks typical TATA-box element. *FEBS Lett* **282**, 87-90 (1991).

62 Emami,K.H., Burke,T.W. & Smale,S.T. Sp1 activation of a TATA-less promoter requires a species-specific interaction involving transcription factor IID. *Nucleic Acids Res* **26**, 839-846 (1998).

63 Smale,S.T., Schmidt,M.C., Berk,A.J. & Baltimore,D. Transcriptional activation by Sp1 as directed through TATA or initiator: specific requirement for mammalian transcription factor IID. *Proc Natl Acad Sci U S A* **87**, 4509-4513 (1990).

64 Hagen,G., Muller,S., Beato,M. & Suske,G. Sp1-mediated transcriptional activation is repressed by Sp3. *EMBO J* **13**, 3843-3851 (1994).

65 De Luca,P., Majello,B. & Lania,L. Sp3 represses transcription when tethered to promoter DNA or targeted to promoter proximal RNA. *J Biol Chem* **271**, 8533-8536 (1996).

66 Lania,L., Majello,B. & De Luca,P. Transcriptional regulation by the Sp family proteins. *Int J Biochem Cell Biol* **29**, 1313-1323 (1997).

67 Majello,B., De Luca,P. & Lania,L. Sp3 is a bifunctional transcription regulator with modular independent activation and repression domains. *J Biol Chem* **272**, 4021-4026 (1997).

68 Ma,Y., Su,Q. & Tempst,P. Differentiation-stimulated activity binds an ETS-like, essential regulatory element in the human promyelocytic defensin-1 promoter. *J Biol Chem* **273**, 8727-8740 (1998).

69 Friedman,A.D. Regulation of immature myeloid cell differentiation by PEBP2/CBF, Myb, C/EBP and Ets family members. *Curr Top Microbiol Immunol* **211**, 149-157 (1996).